James Edgemond Sells 7,782 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,782 shares of the firm’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $366.99, for a total value of $2,855,916.18. Following the sale, the chief financial officer now directly owns 6,426 shares of the company’s stock, valued at approximately $2,358,277.74. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, October 14th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $355.88, for a total value of $2,773,016.96.
• On Monday, October 7th, James Edgemond sold 7,794 shares of United Therapeutics stock. The stock was sold at an average price of $355.54, for a total value of $2,771,078.76.
• On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The stock was sold at an average price of $358.62, for a total transaction of $2,794,367.04.
• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The stock was sold at an average price of $354.04, for a total value of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $350.19 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics Co. has a one year low of $208.62 and a one year high of $377.03. The business’s 50 day simple moving average is $353.45 and its 200 day simple moving average is $311.48. The stock has a market capitalization of $15.53 billion, a PE ratio of 16.56, a PEG ratio of 1.35 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. United Therapeutics’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.24 EPS. As a group, research analysts forecast that United Therapeutics Co. will post 24.72 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. Bank of America cut their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Jefferies Financial Group upped their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, UBS Group raised their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $361.33.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently modified their holdings of the company. Meiji Yasuda Asset Management Co Ltd. increased its position in shares of United Therapeutics by 1.6% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 33 shares during the last quarter. Toronto Dominion Bank lifted its stake in shares of United Therapeutics by 0.8% in the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after acquiring an additional 37 shares during the last quarter. ClariVest Asset Management LLC boosted its stake in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. grew its holdings in United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. raised its stake in shares of United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 48 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.